Compare MRK & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRK | SRPT |
|---|---|---|
| Founded | 2000 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | 2.5B |
| IPO Year | 1994 | 2000 |
| Metric | MRK | SRPT |
|---|---|---|
| Price | $118.77 | $17.64 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 29 |
| Target Price | ★ $125.59 | $25.85 |
| AVG Volume (30 Days) | ★ 7.1M | 2.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | ★ 8.01 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $65,011,000,000.00 | $2,198,237,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | $5.41 | N/A |
| P/E Ratio | ★ N/A | $5.99 |
| Revenue Growth | 1.31 | ★ 15.58 |
| 52 Week Low | $75.40 | $10.42 |
| 52 Week High | $125.14 | $43.92 |
| Indicator | MRK | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 42.49 |
| Support Level | $112.49 | $17.11 |
| Resistance Level | $124.57 | $18.10 |
| Average True Range (ATR) | 2.55 | 0.77 |
| MACD | 0.94 | -0.09 |
| Stochastic Oscillator | 64.89 | 28.85 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.